Cardiometabolic Signatures Drive Divergent HCC Risk Trajectories in MASLD-Associated Advanced Fibrosis
A study of patients with MASLD and advanced fibrosis found that a higher cumulative burden of cardiometabolic risk factors significantly increases the risk of developing hepatocellular carcinoma. The research highlights how specific metabolic profiles correlate with more advanced tumor stages at diagnosis.
Why it matters
Identifying high-risk metabolic clusters allows for more targeted screening and surveillance strategies for liver cancer in patients with metabolic disease.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognised as a systemic disorder driven by cardiometabolic risk factors (CMRF), including obesity, Type 2 diabetes mellitus (T2DM), hypertension, and dyslipidaemia. 1-3 While advanced fibrosis (AF) is a major determinant of hepatocellular carcinoma (HCC) risk, the impact of cumulative metabolic burden and specific CMRF combinations on HCC trajectories remains unclear. 2,3 This study aimed to evaluate how distinct metabolic profiles influence HCC risk in patients with MASLD with AF.
The article reports on medical research findings without subjective commentary.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in